EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Risk Tier, Variant Certainty, and Real-World Care Patterns in Breast Cancer Patients with Germline Alterations in Breast Cancer Susceptibility Genes

Tuba Baydaş iD, İlker Nihat Ökten iD, Filiz Özen, Süheyla Emre iD, İbrahim Çil iD, Metin Eser iD, Adnan Gündoğdu iD, Osman Cem Yılmaz iD, Mahmut Gümüş

Cancers · 07.05.2026 · 18 (10) · 1499

DOI: 10.3390/cancers18101499 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 07.05.2026. Verfasst von Tuba Baydaş und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Istanbul 34722, Türkiye. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The increasing use of multigene germline testing in breast cancer has expanded the detection of pathogenic/likely pathogenic (P/LP) variants and variants of uncertain significance (VUSs) across a broad range of breast cancer susceptibility genes. However, the extent to which pathogenic certainty and penetrance level are associated with distinct clinicopathological phenotypes and management patterns remains incompletely defined.

Methods

In this multicenter retrospective study, we included 405 breast cancer patients with germline alterations in breast cancer susceptibility genes. Patients were classified into three groups: high-penetrance P/LP (n = 116), moderate/low-penetrance P/LP (n = 69), and VUS (n = 220). The primary endpoint was non-luminal invasive breast cancer phenotype, defined as HER2-positive or triple-negative disease versus luminal A/B disease. Multivariable logistic regression was performed to assess the association between genetic group and non-luminal phenotype, adjusted for age at diagnosis and family history. Secondary analyses evaluated management patterns across groups and examined a prespecified non-BRCA cohort.

Results

Patients with high-penetrance P/LP variants were younger at diagnosis and had higher Ki-67 values than those in the other groups. Molecular subtype distribution differed significantly across groups, with triple-negative disease most frequent in the high-penetrance P/LP group (33.9%) compared with the moderate/low-penetrance P/LP (9.8%) and VUS (12.9%) groups. In multivariable analysis, high-penetrance P/LP status was independently associated with increased odds of non-luminal phenotype compared with VUS (OR 1.79, 95% CI 1.06–3.04; p = 0.029), whereas moderate/low-penetrance P/LP status was not (OR 0.96, 95% CI 0.48–1.91; p = 0.911). Management patterns also differed significantly. Initial mastectomy was performed in 65.4% of evaluable patients in the high-penetrance P/LP group, compared with 46.4% in the moderate/low-penetrance P/LP group and 45.5% in the VUS group. Final bilateral mastectomy was observed in 62.6%, 17.5%, and 9.9%, respectively (p < 0.001). In the prespecified non-BRCA analysis, non-BRCA P/LP status was not associated with non-luminal phenotype compared with non-BRCA VUS (OR 0.83, 95% CI 0.40–1.72; p = 0.609).

Conclusions

Among breast cancer patients with germline alterations in breast cancer susceptibility genes, high-penetrance P/LP variants are associated with a distinct clinicopathological profile characterized by younger age at diagnosis, higher proliferative activity, and increased likelihood of non-luminal disease. In contrast, moderate/low-penetrance P/LP variants, especially VUSs, do not show the same degree of phenotype specificity. These findings support a framework in which pathogenic certainty and penetrance level remain central to the interpretation of multigene germline testing in breast cancer.

Schlagwörter

Stichwörter der Autor:innen

breast cancergermline testinghereditary cancermolecular subtypepathogenic variantspenetrancevariants of uncertain significance

Autor:innen und Institutionen

  • Department of Medical Oncology, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Istanbul 34722, Türkiye.
  • Department of Medical Genetics, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Istanbul 34722, Türkiye.
  • Department of Medical Oncology, SBÜ Ümraniye Training and Research Hospital, Istanbul 34764, Türkiye.
  • Department of Medical Genetics, SBÜ Ümraniye Training and Research Hospital, Istanbul 34764, Türkiye.
  • Department of General Surgery, SBÜ Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, Istanbul 34785, Türkiye.
  • Department of Breast Surgery, Istanbul Breast Center, Istanbul 34740, Türkiye.

ORCID-Profile: Tuba Baydaş, İlker Nihat Ökten, Süheyla Emre, İbrahim Çil, Metin Eser, Adnan Gündoğdu, Osman Cem Yılmaz

Zitieren

APA

Baydaş, T., Ökten, İ. N., Özen, F., Emre, S., Çil, İ., Eser, M., Gündoğdu, A., Yılmaz, O. C., & Gümüş, M. (2026). Risk Tier, Variant Certainty, and Real-World Care Patterns in Breast Cancer Patients with Germline Alterations in Breast Cancer Susceptibility Genes. Cancers, 18(10), 1499. https://doi.org/10.3390/cancers18101499

Vancouver

Baydaş T, Ökten İN, Özen F, Emre S, Çil İ, Eser M, et al. Risk Tier, Variant Certainty, and Real-World Care Patterns in Breast Cancer Patients with Germline Alterations in Breast Cancer Susceptibility Genes. Cancers. 2026;18(10):1499. doi:10.3390/cancers18101499

BibTeX
@article{Bayda2026,
  author = {Baydaş, Tuba and Ökten, İlker Nihat and Özen, Filiz and Emre, Süheyla and Çil, İbrahim and Eser, Metin and Gündoğdu, Adnan and Yılmaz, Osman Cem and Gümüş, Mahmut},
  title = {Risk Tier, Variant Certainty, and Real-World Care Patterns in Breast Cancer Patients with Germline Alterations in Breast Cancer Susceptibility Genes},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {10},
  pages = {1499},
  doi = {10.3390/cancers18101499}
}
Kostenlos starten →